You are here
Catrina Stirling
1.
Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c.
Wilson S, Illambas J, Siedek E, Stirling C, Thomas A, Plevová E, Sture G, Salt J.
Vaccine. 2014 Sep 22;32(42):5420-4. doi: 10.1016/j.vaccine.2014.07.102. Epub 2014 Aug 19.
2.
Report on the international workshop on alternative methods for Leptospira vaccine potency testing: state of the science and the way forward.
Stokes W, Srinivas G, McFarland R, Kulpa-Eddy J, Casey W, Walker A, Draayer H, Sebring R, Brown K, Balks E, Stirling C, Klaasen E, Hill R, Rippke B, Ruby K, Alt D, Mukhopadhyay S, Kojima H, Johnson N, Rinckel L, Doelling V, Jones B.
Biologicals. 2013 Sep;41(5):279-94. doi: 10.1016/j.biologicals.2013.06.013. Epub 2013 Jul 23.
3.
Product-specific validation of a serological potency test for release of Leptospira vaccines in the European Union.
Stirling C, Novokova V.
Biologicals. 2013 Sep;41(5):330-1. doi: 10.1016/j.biologicals.2013.06.004. Epub 2013 Jul 10. Review.
4.
A new multivalent (DHPPi/L4R) canine combination vaccine prevents infection, shedding and clinical signs following experimental challenge with four Leptospira serovars.
Wilson S, Stirling C, Thomas A, King V, Plevová E, Chromá L, Siedek E, Illambas J, Salt J, Sture G.
Vaccine. 2013 Jun 28;31(31):3131-4. doi: 10.1016/j.vaccine.2013.05.041. Epub 2013 May 23.
5.
Duration of immunity of a multivalent (DHPPi/L4R) canine vaccine against four Leptospira serovars.
Wilson S, Stirling C, Thomas A, King V, Plevová E, Chromá L, Siedek E, Illambas J, Salt J, Sture G.
Vaccine. 2013 Jun 28;31(31):3126-30. doi: 10.1016/j.vaccine.2013.05.043. Epub 2013 May 23.
6.
Cellular immunity in ASFV responses.
Takamatsu HH, Denyer MS, Lacasta A, Stirling CM, Argilaguet JM, Netherton CL, Oura CA, Martins C, Rodríguez F.
Virus Res. 2013 Apr;173(1):110-21. doi: 10.1016/j.virusres.2012.11.009. Epub 2012 Nov 29. Review.
7.
Foot-and-mouth disease virus replicates only transiently in well-differentiated porcine nasal epithelial cells.
Dash P, Barnett PV, Denyer MS, Jackson T, Stirling CM, Hawes PC, Simpson JL, Monaghan P, Takamatsu HH.
J Virol. 2010 Sep;84(18):9149-60. doi: 10.1128/JVI.00642-10. Epub 2010 Jun 30.
8.
Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost.
Li Y, Stirling CM, Denyer MS, Hamblin P, Hutchings G, Takamatsu HH, Barnett PV.
Vaccine. 2008 May 19;26(21):2647-56. doi: 10.1016/j.vaccine.2008.01.037. Epub 2008 Feb 12.
9.
Perforin expression can define CD8 positive lymphocyte subsets in pigs allowing phenotypic and functional analysis of natural killer, cytotoxic T, natural killer T and MHC un-restricted cytotoxic T-cells.
Denyer MS, Wileman TE, Stirling CM, Zuber B, Takamatsu HH.
Vet Immunol Immunopathol. 2006 Apr 15;110(3-4):279-92. Epub 2005 Dec 1.
10.
Characterization of the porcine neonatal Fc receptor--potential use for trans-epithelial protein delivery.
Stirling CM, Charleston B, Takamatsu H, Claypool S, Lencer W, Blumberg RS, Wileman TE.
Immunology. 2005 Apr;114(4):542-53.